Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Follow-Up Questions
Dare Bioscience Inc의 CEO는 누구입니까?
Ms. Sabrina Johnson은 2017부터 회사에 합류한 Dare Bioscience Inc의 President입니다.
DARE 주식의 가격 성능은 어떻습니까?
DARE의 현재 가격은 $1.83이며, 전 거래일에 increased 1.27% 하였습니다.
Dare Bioscience Inc의 주요 사업 주제나 업종은 무엇입니까?
Dare Bioscience Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Dare Bioscience Inc의 시가총액은 얼마입니까?
Dare Bioscience Inc의 현재 시가총액은 $24.7M입니다
Dare Bioscience Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 6명의 분석가가 Dare Bioscience Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 6명의 매수, 2명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
